Kirsten Drejer on Symphogen sale: A public offering would have been better for everyone

Although former Symphogen CEO Kirsten Drejer is happy that it was Servier that purchased Symphogen, she is disappointed that the firm didn't get the chance to prove itself on the stock exchange.

Photo: Martin Slottemo Lyngstad

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles